



**NEWS RELEASE**  
**FOR MORE INFORMATION CONTACT**

Sam Taylor  
(919) 281-8960  
[staylor@ncbioscience.org](mailto:staylor@ncbioscience.org)

**NCBIO Elects New Officers and Board Members**

(Research Triangle Park, NC – September 29, 2009) Dr. Robert Schotzinger, President and CEO of Viamet Pharmaceuticals, is the new Chairman of the NCBIO Board of Directors. Dr. Schotzinger was elected at a Board meeting following the NCBIO Annual Meeting held on September 29th.

"I look forward to working with the NCBIO Board, members and staff to help continue North Carolina's leadership in the life science industry," stated Dr. Schotzinger. "Having served on NCBIO's Executive Committee, I am well acquainted with the broad efforts that NCBIO has undertaken to improve the climate for our industry, and I want to ensure those efforts continue."

Schotzinger replaces Eric Ward of CropSolution, who has served as Chairman for the past two years. Sam Taylor, who will continue to serve as President of NCBIO, thanked Mr. Ward for his leadership. "Eric has provided strong guidance on a number of issues, particularly related to agricultural biotechnology and capital formation issues, and we appreciate his service." Ken Lee of Hatteras Venture Partners was re-elected Vice-Chairman of the Organization, and Tim Gupton of Hughes Pittman & Gupton LLP was re-elected Treasurer.

Other members elected to NCBIO's Executive Committee are Esther Alegria (Biogen Idec), Peyton Anderson (Affinergy), Chris Capel (Smith Anderson), Ed Field (Aldagen), Susan Thomason (Quintiles Transnational Corporation) and Eric Ward (CropSolution).

Fourteen individuals were elected to the NCBIO Board of Directors at the Annual Meeting September 29<sup>th</sup>. "The Board members represent a diverse group of life science

companies and the service sectors that work with the industry,” stated Sam Taylor, NCBIO President.

New members of the Board include Esther Alegria (Biogen Idec), Peyton Anderson (Affinergy), Terry Costello (Yonkers Industries), Ed Field (Aldagen), Mike Luther (David H. Murdock Research Institute), Adam Monroe (Novozymes), Alan Musso (Targacept), and Crawford Pounds (PricewaterhouseCoopers). The following NCBIO directors were re-elected to the Board: Karen Albritton (CapStrat), Lou Arp (Eisai), Dennis Burns (TCG), Chris Capel (Smith Anderson), Tom Staab (Inspire Pharmaceuticals), and Eric Ward (CropSolution).

Other current members of the Board are Jonathan Bryant (BASF Plant Science), Jeff Collins (Pappas Ventures), Charles Goldstein (BD Technologies), Tim Gupton (Hugh Pittman & Gupton LLP), Matt Jennings, Ken Lee (Hatteras Venture Partners), David Miller (GlaxoSmithKline), Russ Read (National Center Biotechnology Workforce - Forsyth Tech Community College), John Russell (K&L Gates), Robert Schotzinger (Viamet Pharmaceuticals), Susan Thomason (Quintiles Transnational Corporation), Norris Tolson (NC Biotechnology Center), Jan Turek (Biolex Therapeutics), and Mark Weedon (BWA Consulting).

NCBIO is the trade association for North Carolina’s bioscience industry. The Organization has more than 150 members doing business in human and animal therapeutics, diagnostics, medical devices, and agricultural and industrial biotechnology. For more information about NCBIO visit [www.ncbioscience.org](http://www.ncbioscience.org).

###